

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, OR TO OR FOR THE BENEFIT OF U.S. PERSONS OR INTO ANY OTHER JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO.

Göttingen, Germany | May 6, 2026

Sartorius completes placement of bond with a volume of 500 million euros

- Bond with a term of 5 years more than 4 times oversubscribed
- Proceeds to be used for general corporate purposes, including the refinancing of existing debt

The life science group Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed. The bond has a coupon of 3.75 percent per annum. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange.

Sartorius intends to use the net proceeds for general corporate purposes. This includes the refinancing of upcoming maturities, mainly the redemption of a 650 million euro bond with an interest rate of 4.25 percent due in autumn 2026.

“The successful bond issuance further strengthens our balanced debt maturity profile and our long-term financing position. At the same time, the strong demand from investors underscores the capital markets’ confidence in Sartorius and our strategic direction,” said Dr. Florian Funck, CFO and member of Sartorius’ Executive Board.

This press release is for information purposes only and does not constitute an offer to sell or an offer or solicitation to buy or subscribe to securities, nor does it constitute financial analysis or advice or a recommendation relating to financial instruments.

The bonds are not being, and will not be, offered or sold in the United States. Nothing in this press release constitutes an offer to sell or the solicitation of an offer to buy the bonds in the United States or any other jurisdiction. Securities may not be offered, sold or delivered in the United States absent registration under, or an exemption from the registration requirements of, the United States Securities Act of 1933, as amended (the “**Securities Act**”). The bonds have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or delivered, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act).

In the United Kingdom, this announcement is only being distributed to and is only directed at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (ii) high net worth entities falling within Article 49(2) of the Order and (iii) persons to whom it would otherwise be lawful to distribute it (all such persons together being referred to as “relevant persons”). The bonds are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such bonds will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events.

This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

A profile of Sartorius

Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.

Visit our [newsroom](#) or follow Sartorius on [LinkedIn](#).

Contact

Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com